Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

GSK spins off Autifony, which gets £10mm in a Series A commitment; round totals £23.75mm

Executive Summary

Autifony Therapeutics Ltd. (hearing disorders) has spun off from GlaxoSmithKline PLC and concurrently received a Series A commitment of £10mm ($16mm) evenly split by Imperial Innovations Group PLC (which will have 33.6% ownership) and SV Life Sciences. A director from Imperial has joined Autifony’s board. Autifony has collected £3mm in the first tranche; the rest will be realized upon the achievement of milestones, including completion of a major preclinical toxicology study leading to IND or CTA filing (expected within a year). Once certain milestones are met and all of the financing is received, GSK’s stake in Autifony will be reduced from 25.4% to 13.2%.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Spin-Off
    • Venture Financing

Related Companies